| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GALNT7 |
| Uniprot No | Q86SF2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-657aa |
| 氨基酸序列 | PRPDDPSPLSRMREDRDVNDPMPNRGGNGLAPGEDRFKPVVPWPHVEGVE VDLESIRRINKAKNEQEHHAGGDSQKDIMQRQYLTFKPQTFTYHDPVLRP GILGNFEPKEPEPPGVVGGPGEKAKPLVLGPEFKQAIQASIKEFGFNMVA SDMISLDRSVNDLRQEECKYWHYDENLLTSSVVIVFHNEGWSTLMRTVHS VIKRTPRKYLAEIVLIDDFSNKEHLKEKLDEYIKLWNGLVKVFRNERREG LIQARSIGAQKAKLGQVLIYLDAHCEVAVNWYAPLVAPISKDRTICTVPL IDVINGNTYEIIPQGGGDEDGYARGAWDWSMLWKRVPLTPQEKRLRKTKT EPYRSPAMAGGLFAIEREFFFELGLYDPGLQIWGGENFEISYKIWQCGGK LLFVPCSRVGHIYRLEGWQGNPPPIYVGSSPTLKNYVRVVEVWWDEYKDY FYASRPESQALPYGDISELKKFREDHNCKSFKWFMEEIAYDITSHYPLPP KNVDWGEIRGFETAYCIDSMGKTNGGFVELGPCHRMGGNQLFRINEANQL MQYDQCLTKGADGSKVMITHCNLNEFKEWQYFKNLHRFTHIPSGKCLDRS EVLHQVFISNCDSSKTTQKWEMNNIHSVVDHHHHHH |
| 预测分子量 | 73 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GALNT7重组蛋白的3篇参考文献的简要整理：
1. **文献名称**：*GALNT7 promotes pancreatic cancer progression by enhancing O-glycosylation of oncogenic proteins*
**作者**：Mao Y et al. (2019)
**摘要**：该研究揭示了GALNT7在胰腺癌中通过介导关键致癌蛋白(如EGFR)的O-糖基化修饰，促进肿瘤细胞迁移和侵袭的分子机制，并利用重组GALNT7蛋白验证其酶活性对下游信号通路的调控作用。
2. **文献名称**：*Recombinant expression and biochemical characterization of human GALNT7 in a baculovirus system*
**作者**：Schultz MJ et al. (2016)
**摘要**：本研究成功在昆虫细胞中表达并纯化功能性重组GALNT7蛋白，通过体外酶活实验证实其对特定多肽底物的糖基化修饰能力，并分析了其金属离子依赖性等生化特性。
3. **文献名称**：*GALNT7-mediated glycosylation suppresses the tumor suppressor function of MMP14 in hepatocellular carcinoma*
**作者**：Zhang L et al. (2020)
**摘要**：研究证明GALNT7在肝癌中异常高表达，其重组蛋白可通过O-糖基化修饰基质金属蛋白酶MMP14.抑制其降解细胞外基质的功能，从而促进肝癌转移。实验利用重组GALNT7进行了体外糖基化位点验证。
---
*注：上述文献信息为模拟示例，实际引用需以真实发表的论文为准。建议通过PubMed或Google Scholar以“GALNT7 recombinant protein”“GALNT7 O-glycosylation”等关键词检索最新文献。*
GALNT7 (polypeptide N-acetylgalactosaminyltransferase 7) is a key enzyme in the initiation of mucin-type O-glycosylation, a post-translational modification critical for protein stability, trafficking, and function. Belonging to the GALNT family, it catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues of target proteins, forming the Tn antigen—a precursor for extended O-glycan structures. GALNT7 exhibits substrate specificity influenced by peptide sequence and cellular context, with roles in diverse physiological processes, including immune response, cell adhesion, and signaling. Dysregulation of GALNT7 has been linked to diseases such as cancers, where aberrant O-glycosylation contributes to tumor progression, metastasis, and immune evasion.
Recombinant GALNT7 protein is engineered for in vitro studies to dissect its enzymatic mechanisms, substrate preferences, and regulatory pathways. Produced using expression systems like mammalian cells or bacteria, the recombinant form retains catalytic activity while enabling high purity and scalability. It is widely used to study O-glycosylation in cancer biology, identify therapeutic targets, or develop glycoengineering tools for biologics. Researchers also employ it to generate antibodies, screen inhibitors, or validate diagnostic biomarkers associated with glycosylation disorders. Its application extends to structural studies (e.g., crystallography) to elucidate enzyme-substrate interactions. As precision medicine advances, GALNT7 recombinant protein serves as a vital tool for exploring glycosylation's role in disease and therapy development.
×
